Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
IPO-38 (Proliferation Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone SPM260 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, IF, FC |
|---|---|
| Reactivity | Human, Mouse, Rat |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgM, kappa |
| Clone Names | SPM260 |
| Calculated MW | Not Known KDa |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
|---|---|
| Precautions | IPO-38 (Proliferation Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 can be a useful marker of cell proliferation during monitoring of tumor progression.
References
Sidorenko SP et al. Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases. Gematol Transfuziol 1990, 35(4):19-22. Mikhalap SV et al. Monoclonal antibody IPO-38 recognizes a novel nuclear antigen of proliferating cells. In Kishimoto T et al eds. Leukocyte Typing VI, p609-610, Garland Publishing, New York, 1997.Mathews MB et al. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984, 309:374-376
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
